Cobalt(III)-py2en systems as potential carriers of β-ketoester-based ligands

J Inorg Biochem. 2023 Nov:248:112345. doi: 10.1016/j.jinorgbio.2023.112345. Epub 2023 Aug 2.

Abstract

Two cobalt(III) complexes containing different β-ketoesters, namely [CoIII(L1)(py2en)](ClO4)2·H2O (1) and [CoIII(L2)(py2en)](ClO4)2 (2) (py2en = N,N'-bis(pyridin-2-ylmethyl)ethylenediamine; L1- = methylacetoacetate; L2- = ethyl 4-chloroacetoacetate) have been prepared and investigated as prototypes of bioreductive prodrugs. The presence of β-ketoester and py2en ligands in 1 and 2, as well as the perchlorate counterions, was supported by IR spectroscopy and CHN elemental analysis. The composition molecular structure of both complexes was confirmed by NMR spectroscopy and ESI mass spectrometry. Structural information was also obtained for 2via X-ray diffraction analysis. The redox properties indicate that 1 and 2 are suitable for reduction under biological conditions. Investigation of DNA-interacting suggest that 1 and 2 bind DNA via electrostatic forces. Both complexes may be employed as possible platforms for the delivery of biologically active compounds, since their reaction with ascorbic acid in PBS at pH 6.2 and 7.4 at 37°C results in the release of the β-ketoester ligands upon Co(III)/Co(II) reduction.

Keywords: Anticancer drugs; Cobalt(III) complexes; DNA binding; Hypoxia-activated drug delivery; Prodrugs; β-Ketoester.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cobalt* / chemistry
  • Crystallography, X-Ray
  • Ligands
  • Molecular Structure
  • Prodrugs* / chemistry

Substances

  • Cobalt
  • Ligands
  • Prodrugs